Tango Therapeutics Inc Earnings

The next earnings date for Tango Therapeutics Inc is November 5, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Tango Therapeutics Inc Earnings

Report Date	Estimated Earnings Per Share
11/05/2025	$-0.18

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Tango Therapeutics Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
08/05/2025	---	$-0.35	-1.07%
05/06/2025	Before Market	$-0.36	-4.08%
03/17/2025	Before Market	$-0.34	0.82%
11/06/2024	Before Market	$-0.27	27.03%
08/07/2024	Before Market	$-0.24	29.41%
05/08/2024	Before Market	$-0.35	-12.90%
03/18/2024	Before Market	$-0.32	-14.29%
11/08/2023	Before Market	$-0.23	32.35%
08/07/2023	Before Market	$-0.23	32.35%
05/09/2023	Before Market	$-0.32	8.57%
03/27/2023	Before Market	$-0.33	5.71%
11/10/2022	Before Market	$-0.33	-3.13%
08/10/2022	Before Market	$-0.28	12.50%
05/11/2022	Before Market	$-0.29	-3.57%
03/28/2022	Before Market	$-0.25	7.41%
11/09/2021	Before Market	$-0.28	0.00%
08/06/2021	After Market	$-0.16	-10.34%
05/14/2021	---	$-0.01	---
03/31/2021	---	$-0.00	---
11/13/2020	---	$-0.00	---
07/30/2020	---	$0	---

More About Tango Therapeutics Inc

Website

https://www.tangotx.com

Country

USA

Full Time Employees

155

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

“Tango Therapeutics Inc Earnings” Can Refer to the Tango Therapeutics Inc Earnings Date

Some people say “Tango Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Tango Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Tango Therapeutics Inc Stock on the Earnings Date

If you own Tango Therapeutics Inc stock (TNGX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Tango Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Tango Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Tango Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about Tango Therapeutics Inc earnings or anything else related to the stock market.